Skip to main content
Premium Trial:

Request an Annual Quote

LifeArc Providing £5M for COVID-19 Study on Genomics of Severe Disease

NEW YORK – Medical research charity LifeArc said on Monday that it is providing £5 million ($6.9 million) in funding to the GenOMICC consortium to support the GenOMICC COVID-19 study.

The consortium, which launched the study in May 2020 in partnership with Genomics England, is using genomics to investigate the genetic factors underlying disease severity and to increase understanding about the disease. The researchers are hoping that they'll be able to compare the genomes of people who had severe illness with those who had more manageable symptoms.

The consortium is anticipating that the study data will provide insights into the fight against COVID-19, as well as other coronavirus infections in the future. They're also hoping that the study could also provide insights on therapeutic and preventative strategies for future pandemics.

The partnership with Genomics England was formed to enable large-scale and rapid whole-genome sequencing and analysis for NHS COVID-19 patients by using Genomics England's sequencing and analysis resources. LifeArc's funding will add to £4.6 million of additional funding that has already been announced by the UK Department of Health and Social Care and will support the costs of patient enrollment, sample acquisition, sample processing, and bioinformatics analysis, the charity said.

"This initiative moves us forward to better understand the heterogeneity of responses to COVID amongst people, considering that genetic variation may play a key differentiating and therefore predictable role," LifeArc CEO Melanie Lee said in a statement. "It is hoped that this program will provide rapid insights that can inform accurate diagnostics and potential targets for drug development. We hope this work will also help inform the 15 clinical studies that we have funded into investigating existing drugs for efficacy in COVID patients as part of the £27 million LifeArc has now allocated to research projects to tackle the COVID-19 pandemic."

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.